Home › Crohn's Disease › Ohio
Crohn's Disease clinical trials in Ohio
29 studies for Crohn's Disease are looking for participants at sites in Ohio.
Cities in Ohio
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Dayton Gastroenterology - Englewood /ID# 284065, Englewood
- Gastro Intestinal Research Institute of Northern Ohio /ID# 283860, Westlake
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 29, 2026 · NCT07697456A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Great Lakes Gastroenterology Research, LLC ( Site 5016), Mentor
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 29, 2026 · NCT06430801A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Great Lakes Gastroenterology Research, LLC, Mentor
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07499232A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- Great Lakes Gastroenterology Research, LLC, Mentor
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT06233461Non-nutritive Sweeteners in Inflammatory Bowel Disease
- UH Minoff Health Center, Chagrin Falls
- University Hospitals Cleveland Medical Center, Cleveland
- UH Westlake Health Center, Westlake
RecruitingHealthy volunteers welcome
Ages 18 to 70 · All sexes · Updated Sep 25, 2026 · NCT07769437A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Cincinnati Children's Hospital Medical Center, Cincinnati
RecruitingPhase 3
Ages 3 and older · All sexes · Updated Sep 25, 2026 · NCT06663332Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- University of Cincinnati /ID# 265589, Cincinnati
- The Ohio State University /ID# 265577, Columbus
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT06548542Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 24, 2026 · NCT06937099A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Ohio Gastroenterology Group Inc.-Site Number: 8400006, Columbus
- Medical Associates Research Group-Site Number: 8400063, Columbus
- OSU Wexner Medical Center-Site Number: 8400077, Columbus
- and 1 more
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 23, 2026 · NCT07184944An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology & Hepatology Specialists, Inc.-Site nUmber: 8400139, Canton
- University Hospitals Cleveland Medical Center-Site Number: 8400073, Cleveland
- Ohio Gastroenterology Group Inc.-8400006, Columbus
- and 5 more
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 23, 2026 · NCT07184931Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT03816345A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Cleveland Clinic - Cleveland /ID# 256453, Cleveland
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Sep 23, 2026 · NCT05995353A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Gastro Health Research - Cincinnati, Cincinnati
- DSI Research Northridge LLC, Dayton
- Gastro Health Research - Liberty Township, Liberty Township
- and 3 more
RecruitingPhase 4
Ages 18 to 80 · All sexes · Updated Sep 15, 2026 · NCT06581328A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- University of Cincinnati, Cincinnati
- Ohio Gastroenterology group, Inc., Columbus
- Great Lakes Gastroenterology Research, LLC, Mentor
- and 1 more
RecruitingPhase 4
Ages 18 to 70 · All sexes · Updated Sep 9, 2026 · NCT06045754A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Great Lakes Gastroenterology Research, LLC, Mentor
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07577843Ultrasound-Guided Versus Standard Margin Selection in Ileocecal Resection of Terminal Ileal CD
- Cleveland Clinic, Cleveland
Recruiting
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT07680283A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Childrens Medical Center, Dayton
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Aug 24, 2026 · NCT05509777Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- University of Cincinnati, Cincinnati
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT07237516Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- UH Cleveland Medical Center /ID# 262188, Cleveland
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Jun 24, 2026 · NCT06332534A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- University Children's Clinic, Cleveland
- Cleveland Clinic, Cleveland
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Jun 22, 2026 · NCT06405087Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Cincinnati Children's Hospital Medical Center, Cincinnati
- UH/Rainbow Babies and Children's Hospital, Cleveland
- Nationwide Children's Hospital, Columbus
RecruitingPhase 4
Ages 6 to 17 · All sexes · Updated May 27, 2026 · NCT05781152A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- University Hospitals Cleveland Medical Center - 11100 Euclid Ave, Cleveland
RecruitingPhase 3
Ages 2 and older · All sexes · Updated May 7, 2026 · NCT05442567Precise Infliximab Exposure and Pharmacodynamic Control
- Cincinnati Children's Hospital, Cincinnati
- Cleveland Clinic Children's Hospital, Cleveland
- Nationwide Children's Hospital, Columbus
RecruitingPhase 2/3
Ages 6 to 22 · All sexes · Updated May 5, 2026 · NCT05660746A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- University Hospitals Cleveland Medical Center, Cleveland
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated May 5, 2026 · NCT04779320Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- OSU Inflammatory Bowel Disease Center, Hilliard
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Apr 27, 2026 · NCT06456593A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Cincinnati
- Mirador Therapeutics Selected Site, Liberty Township
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Mar 12, 2026 · NCT07113522Treatment of Moderate to Severe Refractory Crohn's Disease
- Cleveland Clinic, Cleveland
RecruitingPhase 1/2
Ages 18 to 65 · All sexes · Updated Dec 10, 2025 · NCT06721962Evaluation of the SMART IBD App in Pediatric IBD
- Cincinnati Children's Hospital Medical Center, Cincinnati
Recruiting
Ages 13 to 17 · All sexes · Updated Nov 21, 2025 · NCT07195123Development of a Novel Endoscopic Index and Patient-reported Outcome Measure for Clinical Trials in Participants With Permanent Ileostomy
- Cleveland Clinic Foundation, Cleveland
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 12, 2025 · NCT06670638From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.